If we were to definitively rank the meals that one eats over the course of the day, I argue that breakfast would be at the top of everyone’s list. Now, you may be wondering why breakfast is clearly the winner. Well, first of all, great question. Good on you for being inquisitive. And second of all, because breakfast incorporates every part of a well-balanced diet while serving foods that satisfy every craving a person could imagine. Say you’re in the mood for something savory, well, eat a savory crepe for breakfast or perhaps a bagel with smoked salmon. Maybe savory isn’t your jam, but something sweet is. Travel back four words in the last sentence and spread that on toast, my friend. But what if you’re trying to eat healthy, and you’re avoiding breads and salty food. Might I suggest to you my friend and yours, the scrambled egg.
Getting hungry? Well, here’s what you missed in the news yesterday.
“N” is for Neutrality
Net neutrality has kept American internet-users from being taken advantage of by their service providers but, considering that he’s a fan of big business, President Trump insisted we repeal the protections. Naturally, the Democratic leadership had a bone to pick with Donald regarding his actions and so they introduced the “Save the Internet Act” a few months back. The concise, two-page bill seeks to restore 2015’s net neutrally rules and, as of Wednesday, the bill was passed in the House of Representatives.
According to several reports, the bill, which was introduced yesterday, was heavily debated and discussed in the house. Of course, a gaggle of staunch Republican members of the house question both the morality of the lawmakers responsible for the bill as well as why the bill was even introduced in the first place.
Rep. Burgess (R-TX) was one such character making the bill’s proceedings longer than they needed to be when he asked that the Government Accountability Office issue a report on the effect of edge provers on internet freedoms, according to TechCrunch. For those unfamiliar with the term “edge provider,” these are companies that operate online sites that customers connect to over the internet like Google, Amazon, and Netflix. Rep. Burgess being the conservative that he is expressed his concerns that free access to the internet may interrupt the revenue streams for edge providers when, in fact, this is not the case.
The Spy Who Trumped Me
In an interesting turn of events, Attorney General William Barr told several law officials that “spying did occur” on President Donald Trump’s presidential campaign, but said nothing more after introducing the idea. Seriously, after he said this, all major media outlets have been doing everything in their power to try and figure what Barr was talking about.
CNN believes Barr was referring to Carter Page, a man who served as foreign policy adviser to Trump during his campaign but was then surveilled by the FBI for a minute.
“The FBI believes that Page has been collaborating and conspiring with the Russian government,” the application stated, adding that “there is probable cause that such activities involve or are about to involve violations of the criminal statutes of the United States.”
–Federal Bureau of Investigation
Will Biotech Stocks Soar Into 2020?
The stock market has been on a wild ride this year and December has shown no difference. When it comes down to it, making money in the stock market is simple. But it isn’t easy; let me explain.
For instance, if a sector is on the upward trajectory then it makes complete sense to have a look at some of the stocks in that arena. But then again, even if the sector is hot, it doesn’t mean every stock within it is.
Regardless, among the sectors that have shown impressive growth over the past few years biotech remains positive. and many investors have managed to make handsome returns. Here is a look at two biotech stocks that are worth considering at this point.
Tonix Pharmaceuticals Holding
The first biotech stock that could be out into the watch list is that of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) after the company made an important announcement. Tonix announced that it has been granted a patent by the European Patent Office for “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Mannitol”.
The patent gives Tonix access to as many as 14 claims and also gives the company exclusive rights up until 2034. The development is a significant one and could have far-reaching implications for Tonix’s business in the years to come.The news was well-received by the markets as well and the stock rallied by as much as 23% on Thursday.
The other stock that could be taken under consideration is the VBI Vaccines Inc (NASDAQ:VBIV). The company made a major announcement with regards to the Phase 1/2A study of its cancer vaccine immunotherapeutic In recurrent glioblastoma (GBM) patients medicine VB1-1901.
The company announced that it presented the data regarding the medicine at the 24th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology. The event in question is an influential one and is a substantial achievement for VBI. The stock rallied by as much as 50%.
Stock Price Newsletter – December 13, 2019
2 Biotech Stocks To Watch Before Next Week
Biotech has been one of the hottest sectors to invest in for quite a few years. Nowadays, investors are almost always on the lookout for the next big thing from among those stocks. However, when it comes to identifying stocks, an investor needs to do his fair share of research and then decide on his next course of action.
Additionally, one could also watch the market closely and keep track of the latest movements in penny stocks in order to identify potential winners. Here is a look at two biotech stocks which could be of interest to investors.
Biotech Stocks To Watch: Marinus Pharmaceuticals
The first biotech stock to bring under consideration is Marinus Pharmaceuticals Inc (NASDAQ:MRNS) which has made significant gains on Wednesday on the back of an important announcement.
On Wednesday, the company announced that it is going to make a simultaneous public offering of its common stock and private placement. The total value of these two offerings is going to be $65 million. The news resulted in a 38% bump in the stock price in yesterday’s trading session.
Earlier this week, the company announced that it has started its Phase 2 trial for its product ganaxolone as well. The medicine in question is supposed to treat tuberous sclerosis complex and it goes without saying that it is a significant milestone for Marinus.
Biotech Stocks To Watch: Diffusion Pharmaceuticals
The other biotech stock that could be worth tracking is that of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN). The company announced positive data with regards to the Phase 3 study its product Trans Sodium Crocetinate (TSC) plus standard of care (SOC). The data showed that there was an improvement in the condition of patients suffering from inoperable glioblastoma multiforme.
It proved to be a major trigger for the Diffusion stock and after the announcement was made on Tuesday, the stock has rallied by as much as 31.40%. It is a stock that could be worth watching over the coming days.
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
Search Stock Price (StockPrice.com)
Biotechnology2 weeks ago
3 Pharma Stocks To Watch In December 2019
Featured2 weeks ago
Stock Price Monday Morning Update – December 2, 2019
Newsletter2 weeks ago
Stock Price Thursday Morning Update – December 5, 2019
Featured1 week ago
Stock Price Newsletter – December 6, 2019
Featured1 week ago
Stock Price Monday Morning Newsletter – December 9, 2019
Featured2 weeks ago
Stock Price Newsletter – December 3, 2019
Featured2 weeks ago
Stock Price Wednesday Morning Update – December 4, 2019
Entertainment2 weeks ago
Stocks To Buy Or Sell As Streaming Wars Heat Up, Disney (DIS)